All In MedTech

Device Trial Radar · NCT06689423

Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay

Clinical Performance Evaluation of the VitaSIRO Solo™ SARS-CoV-2/Flu/RSV Assay

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,268

Actual

Start

Nov 1, 2024

Primary completion

Dec 18, 2025

Study completion Dec 18, 2025

Sponsor

Lead sponsor
Credo Diagnostics Biomedical Pte. Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
Medical College of Wisconsin
First posted
Nov 14, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to demonstrate the clinical performance of the VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay in detecting SARS-CoV-2, Flu A, Flu B and RSV in symptomatic population. The primary aim is to determine the PPA/NPA against a comparator assay. The secondary aim is to determine the diagnostic sensitivity, specificity, PPV and NPV against the standard-of-care test. Each subjects will be asked to provide both nasal swab (NS) and nasopharyngeal swab (NPS) for testing purposes.

Conditions

  • SARS-CoV-2
  • COVID-19
  • RSV
  • Influenza

Interventions

  • Credo POCT DeviceDevice

    Testing Credo's POCT device for respiratory viruses detection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Positive percent agreement(PPA) and Negative percent agreement (NPA)Time frame: In 7 days after specimen collection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Credo Diagnostics Biomedical Pte Ltd. Taiwan Branch

    New Taipei City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.